Nonadherence in nearly one-third of patients with HTN

Nonadherence in nearly one-third of patients with HTN

(HealthDay)—More than 30 percent of patients with hypertension are not adherent to antihypertensive drug therapy, according to a study published online Nov. 3 in the Journal of Evaluation in Clinical Practice.

Jerome J. Federspiel, M.D., Ph.D., from the University of North Carolina at Chapel Hill, and colleagues linked Atherosclerosis Risk in Communities records to Medicare claims for cohort participants reporting without prevalent cardiovascular disease. Medicare Part D claims data were used to assess antihypertensive medication adherence, measured as more than 80 percent proportion days covered.

The researchers found that for 31.5 percent of the 1,826 participants with hypertension and Part D coverage there was no antihypertensive class with medication adherence of more than 80 percent proportion days covered in the three months preceding the report of hypertension. Positive predictors of use included female gender and diabetes, after adjustment for confounding variables; African-American race and current smoking were negative predictors. After adjustment, the correlation between receiving no therapy and a composite end point of through 2012 was not statistically significant; the adjusted associations with Medicare inpatient days or payments were also not statistically significant.

"Despite having medical and prescription coverage, nearly a third of hypertensive participants were not adherent to antihypertensive drug therapy," the authors write. "Differences in clinical outcomes associated with nonadherence, though not statistically significant, were consistent with results from randomized trials."

More information: Full Text (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.

Citation: Nonadherence in nearly one-third of patients with HTN (2016, November 7) retrieved 3 July 2024 from https://medicalxpress.com/news/2016-11-nonadherence-one-third-patients-htn.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Fall risk up with initiation, intensification of HTN meds

0 shares

Feedback to editors